

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (Cancelled).

4. (Currently Amended) A method comprising transplantation of insulin producing cells in the form of individually isolated islets to a patient suffering from insulin dependent diabetes mellitus (IDDM),
wherein said individually isolated islets are modified by irreversible adsorption with a clotting inhibiting agent comprising heparin or a fraction or derivative thereof,
wherein said individual islet cells are each separately coated with heparin or a fraction or derivative thereof by preincubation of islets in a solution containing heparin or a fraction or derivative thereof,
wherein said clotting inhibiting agent acts to inhibit clotting or reduce clotting.

Claims 5-7 (Cancelled).

8. (Previously Presented) The method according to claim 4, wherein more than one clotting inhibiting agent is used.

9. (Previously Presented) The method according to claims 4, wherein the clotting inhibiting agent is supplemented by an inhibitor of complement.

Claim 10 (Cancelled).

11. (Previously Presented) A method for increasing survival of islet cells according to claim 14, in connection with transplantation of insulin producing cells to patients with insulin dependent diabetes mellitus (IDDM), comprising inhibiting of clotting, monitored as reduced generation of thrombin-antithrombin complex (TAT complex).

Claims 12-13 (Cancelled).

14. (Withdrawn/Amended) Isolated islets comprising insulin producing cells, wherein the islets are individually coated with a clotting inhibiting agent on the islet surface.

15. (Withdrawn) Isolated islets of claim 14, wherein the clotting inhibiting agent is an anticoagulant.

16. (Withdrawn) Isolated islets according to claim 15, wherein the anticoagulant is heparin or a fraction or derivative thereof.

17. (Withdrawn) Isolated islets according to claim 16, wherein the isolated islet cells are coated with heparin

or a fraction or derivative thereof by preincubation of islets in a solution containing heparin or a fraction or derivative thereof.

18. (Withdrawn) Isolated islets of claim 14, wherein the clotting inhibiting agent is an inhibitor of platelet activation.

19. (Withdrawn) Isolated islets according to claim 18, wherein the clotting inhibiting agent is a RGD containing peptide or a monoclonal antibody which inhibits the interaction of platelet integrins with their specific ligands.

20. (Withdrawn) Isolated islets according to claim 19, wherein the clotting inhibiting agent is a monoclonal antibody or a peptide directed against the Fc receptor on platelets.

21. (Withdrawn) Isolated islets according to claim 20, wherein said islets are coated with more than one clotting inhibiting agent.

22. (Withdrawn) Isolated islets according to claim 20, wherein said islets are also coated with an inhibitor of complement.

23. (Withdrawn) Isolated islets according to claim 21, wherein said islets are also coated with an inhibitor of complement.

24. (Withdrawn/Amended) Isolated cells comprising islets of Langerhans, wherein the islets are individually coated with a heparin conjugate on the islet surface.

25. (Withdrawn/Amended) Method of production of a composition for treatment of insulin dependent diabetes mellitus, IDDM, comprising coating isolated islets with a clotting inhibiting agent to provide individually coated isolated islets.

26. (New) A method of using the isolated islets of claim 14, comprising

injecting said islets individually coated with a clotting inhibiting agent into the bloodstream of a patient suffering from insulin dependent diabetes mellitus (IDDM).